Quest for the Holy Grail
Pursuit of sea lice vaccine hot topic at Pharmaq’s annual get together
IT WAS on day two of Pharmaqademy 2017, held in Inverness last month, that Ben North updated delegates on some changes that have been implemented at Fordingbridge, the home of Pharmaq in the UK. Ben him Pharmaq here to the post of director of global Hampshire.
UK business now rests with Anne Day, who business as usual at Pharmaq, although, as hitherto have been quite a challenge for a company with 220 employees.
- SmoltVision, which helps salmon producers determine when their smolts are ready to be transferred to sea, was presented by Elise Hjelle, who is managing the process for the company.
- upon an analysis of ATPase enzyme levels, but measuring readiness for transfer, the results of which can be conveyed to producers within 24 hours of receiving the samples. The service has Faroes and Iceland and the company is now launching the system in Scotland and Ireland.
- sessing when they are capable of being transferred to seawater remains a challenge and is currently based on size (usually around 100 grams).
However, according to Elise, and to trout producers present at Phar
licensed therapeutant, AMX.
The current lice vaccine research project at Pharmaq commenced in respect to three candidate proteins, Bjørn Brudeseth was under no illusions about the long-term nature of the hunt for this Holy Grail and
A quicker return on new research in the realm of sea lice may well outlined the results of a project, supported by Pharmaq, that is trying to determine what makes some sea lice resistant to deltamethrin.
- available lice treatments.
- ported Bjørn’s view that the pursuit of a vaccine against parasites, while challenging, is certainly an enterprise worth pursuing. She presented - response from the host.
an M. viscosa component, it is characterising isolates from a pool of
samples collected from salmon, trout and, under the auspices of a SAIC
- -
-
- -
- manager.